About This Study
Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV/PTLD) is a virus that can happen after receiving a solid organ transplant or allogenic cell transplant. The purpose of this study is to learn more about a new treatment called tabelecleucel. We want to see how well this treatment works for patients with this virus who did not get better with a treatment called rituximab or rituximab plus chemotherapy.
What Activities Are a Part of this Study?
- Informed Consent Review
- After Study Follow-Up Activities
- Review of Medical History
- Physical Examinations
- Phone Calls and/or Emails
- Study Visits and Consultations
- Surveys/Questionnaires
- Laboratory and Imaging Tests
- Specimen Sample Collection
Age & Gender
- 18 - 100 years old
- All Genders
Language
- This study enrolls English and Spanish speakers
Additional Study Information
- No compensation provided
- Reimbursement offered
Study Locations
- Greater Charlotte, NC